Loading
Latest filing published 10 Sept 2026 for Metagenomi Therapeutics, Inc., €356.
Matthew Wein discloses dealings in Metagenomi Therapeutics, Inc. to SEC (Form 4). Between 1 April 2024 and 8 September 2026, the trades on record add up to 11 filings.
The open-market record consists of 6 sales worth €3,576, with no purchase. Outside the open market, there are 5 share grants. So far in 2026, the count stands at no purchases and 2 sales.
Most recently, on 10 September 2026, the filings show an open-market sale worth €356 in Metagenomi Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations